The following are the decisions for drugs that have been considered by the drug advisory committee for inclusion to the WSIB formularies:

• Aripiprazole (PDF) 
• Benzodiazepines (PDF)
• Botulinum Toxin A: Botox^®,Botox Cosmetic^®, Xeomin^®
• Buprenorphine (Opioid use disorder)
• Buprenorphine (Treatment of chronic pain)(PDF)
• Calcitonin Gene-Related Peptide Monoclonal Antibodies in prevention of migraine
• Cannabinoid: Nabilone(PDF)
• Compounded Topical Analgesics (PDF)
• Corticosteroid injections (musculoskeletal conditions)*
• Desvenlafaxine (PDF)
• Diclofenac Sodium Solution 1.5%(PDF)
• Duloxetine (PDF)
• Escitalopram (PDF)
• HIV Post-Exposure Prophylaxis (PDF)
• Hypnotics: Zopiclone, Trazodone and Tryptophan(PDF
• Ketamine and esketamine
• Oxycodone/Naloxone Controlled Release(PDF)
• Paliperidone (PDF)
• Piroxicam (PDF)
• Pregabalin (PDF)
• Skeletal Muscle Relaxants (PDF)
• Tapentadol Controlled Release (PDF)
• Tramadol (PDF)
• Viscosupplements (PDF)
• Ziprasidone(PDF)